 |
 |
|
Central Hungarian Innovations Center Solvo Biotechnology, a privately held biopharmaceutical company has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays. The company offers drug discovery products and services to pharmaceutical, biotechnology and consumer goods industries, relevant to many therapeutic areas and product categories. All major pharma and biotech companies use SOLVO's assays, either in-house, or as contracted research. Efflux and various uptake transporters play a key role in the function of the Blood-Brain Barrier (BBB), the Blood-CSF barrier, the Blood-Testis barrier, the Intestinal epithelia (absorption), the Airway epithelia, the Liver epithelia and the Kidney epithelia. SOLVO products can be used to study the transport properties of these pharmacological barriers. SOLVO's mainstream products are its in vitro assay systems to detect the interaction of test compounds with a wide array of ABC Transporter proteins, and cell lines expressing various uptake transporter proteins used for in vitro ADME/Tox, oncology drug research and MDR modulating agent discovery. SOLVO's unique technology platform is built on our core capabilities for expression of a wide array of human ABC transporters (MDR1, MDR2/3, MRP1, MRP2, MRP3, MRP4, MRP5, MRP6, MXR, BSEP and others) and rodent (rat, mouse) transporters in various expression systems (e.g. baculovirus-based insect cell); functional characterization of proteins (ATPase, transport and binding data); identification of new drug targets on ABC transporters; and development of various cell lines expressing a range of pharmacologically relevant uptake transporter proteins. In the EUSTROKE project, SOLVO will use its expertise in the field of transporter to profile the transporter expression in BBB models. In vitro assay systems are available to detect the interaction of drugs and antioxidant natural compounds with transporters relevant in the treatment of stroke. The effect of ultrasound and microbubbles (stable and inertial cavitation) on the transporter will also be studied.
Project StaffDr. Krisztina Herédi-Szabó (Senior Scientist), coordination, membrane assays Dr. Péter Krajcsi (Chief Scientific Officer), strategic planning Dr. Zsolt Holló (Medical Director & Chief Operations Officer), advisor on clinical aspects Gábor Heltovics (Business Development Director), marketing Judit Jánossy (Senior Scientific Associate) medical writing, administration Dr. Enikő Ioja (Principal Scientist), cellular assays Franciska Erdő (Senior Scientist), brain microdialysis Márton Jani (Scientist), monolayer efflux assays Krisztina Vukman (Scientist), membrane assays Viktoria Juhász (scientist) cell culture Eszter Illés Patakiné (technician), membrane assays
|
